PharmaCyte Biotech and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.
Stock Symbols

PharmaCyte Biotech Bioengineers Cell Line for Cannabis Program to Treat Cancers

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that its research partner, the University of Northern Colorado, has bioengineered a human cell line designed to activate a cannabinoid prodrug in its quest to develop a Cell-in-a-Box(R)/cannabinoid therapy for serious forms of cancer, particularly brain cancer.
Stock Symbols

PharmaCyte Biotech Advances Manufacturing Process for Clinical Trial in Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
Stock Symbols

PharmaCyte Biotech Nearing Major Milestone–An Open IND with the FDA

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event–an “open” or approved Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for its development of a treatment for patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).
Stock Symbols

PharmaCyte Biotech Releases CEO Interview from The Big Biz Show

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that it has added a new CEO interview to the company’s website. Chief Executive Officer, Kenneth L. Waggoner, was featured on “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio program, on Friday, January 18th.
Stock Symbols

PharmaCyte Discusses Pancreatic Cancer Clinical Trial with Medpace’s Medical Monitor Dr. Lyon Gleich

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),released an interview with Lyon Gleich, M.D., of Medpace, a global full-service clinical contract research organization (CRO). Dr. Gleich serves as the Medical Monitor and key team member of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
Stock Symbols

The Growing Demand for Cancer Treatment is Raising Immunotherapy Dependence

According to data compiled by Global Market Insights, the biotechnology market was valued at USD 330.3 Billion in 2015 and is projected to exceed USD 775.2 Billion while growing at a CAGR of 9.9% from the forecast period between 2016 to 2024. The growing demand for technology like DNA sequencing, fermentation, recombinant technology and tissue engineering is expected to drive the market. Other technologies that are dominant in the market are PCR, nano-biotechnology, chromatography, and cell-based assays, which are projected to rapidly expand and other applications such as immunotherapy are also quickly emerging. According to MarketsandMarkets, the global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.9 Billion in 2016 and grow at a CAGR of 14% from 2016 to 2021. Regen BioPharma, Inc. (OTC: RGBP), ARCA Biopharma, Inc. (NASDAQ: ABIO), Onconova Therapeutics, Inc. (NASDAQ: ONTX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), PharmaCyte Biotech, Inc. (OTC: PMCB)
Stock Symbols

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q&A Series

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced the latest in a series of Q&A articles that PharmaCyte conducts with some of the key team members of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). Dr. Matthias Lohr, of the famed Karolinska Institute in Stockholm, Sweden, answers a host of questions related to PharmaCyte’s upcoming clinical trial design. Dr. Lohr is the Chairman of PharmaCyte’s Scientific Advisory Board, and he was the Principal Investigator of the two earlier clinical trials using the Cell-in-a-Box(R) technology in patients with advanced metastatic pancreatic cancer.
Stock Symbols

PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that it has successfully completed the comprehensive characterization of its proprietary cell clone known as 22P1G.
Stock Symbols